Citations

Clear

152 citation(s) found for "Tobin, M D".

Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients
Fereidan‐Esfahani, Mahboubeh, Decker, Paul A. , Weigand, Stephen D. , López‐Chiriboga, A. Sebastian , Tillema, Jan‐Mendelt , Lucchinetti, Claudia F. , Eckel‐Passow, Jeanette E. , Tobin, W. Oliver , Lopez-Chiriboga, A Sebastian , Lucchinetti, Claudia F , Tobin, W Oliver , Decker, Paul A. , Flanagan, Eoin P.

Mayo Clinic

Annals of Clinical and Translational Neurology | July 14, 2023 | Volume: 10 | Issue: 9 | Pages: 1544-1555

10.1002/acn3.51844 | PMID 37443413 Get It

AbstractObjectiveTo describe demographic, clinical, and radiographic features of tumefactive demyelination (TD) and identify factors associated with severe attacks and poor outcomes.MethodsRetrospective review of TD cases seen at Mayo Clinic, 1990–2021.ResultsOf 257 patients with TD, 183/257 (71%) fulfilled the 2017 multiple sclerosis (MS) McDonald criteria at the last follow‐up, 12/257 (5%) had myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), 0 had aquaporin‐4‐IgG seropositive neuromyelitis optic spectrum disorders (AQP4+ NMOSD), and 62/257 (24%) were cryptogenic. Onset before age 18 was present in 18/257 (7%). Female to male ratio was 1.3:1. Cerebrospinal fluid oligoclonal (CSF) bands were present in 95/153 (62%). TD was the first demyelinating attack in 176/257 (69%). At presentation, 59/126 (47%) fulfilled Barkhof criteria for dissemination in space, 59/100 (59%) had apparent diffusion coefficient (ADC) restriction, and 57/126 (45%) had mass effect. Despite aggressive clinical presentation at onset, 181/257 (70%) of patients remained fully ambulatory (Expanded Disability Status Scale [EDSS] ≤4) after a 3.0‐year median follow‐up duration. Severe initial attack‐related disability (EDSS ≥4) was more common in patients with motor symptoms (81/143 vs. 35/106, p < 0.0001), encephalopathy (20/143 vs. 2/106, p < 0.0001) and ADC restriction on initial MRI (42/63 vs. 15/33, p = 0.04). Poor long‐term outcome (EDSS ≥4) was more common in patients with older onset age (41.9 ± 15 vs. 36.8 ± 15.6, p = 0.02) and motor symptoms at onset (49/76 vs. 66/171, p < 0.0001).InterpretationMost TD patients should be considered part of the MS spectrum after excluding MOGAD and NMOSD. Motor symptoms and older age at presentation portend a poor outcome.
Teaching NeuroImage: Olfactory Stem Cell Injection Inducing Actively Secreting Respiratory Epithelium in a Cervical Syrinx
Rotter, Juliana , Kumar, Rahul , Nesvick, Cody L. , Krauss, William E. , Tobin, W. Oliver , Tobin, W Oliver , Nesvick, Cody L , Giannini, Caterina

Mayo Clinic

Neurology | July 3, 2023 | Volume: 101 | Issue: 11 | Pages: 497-498

10.1212/wnl.0000000000207463 | PMID 37400242 Get It

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma (AM) in patients with concomitant chronic lymphocytic leukemia (CLL).
Cass, Samuel , Keung, Emily Z. , Walsh, Danielle M. , Davies, Michael A. , McQuade, Jennifer L. , Hampel, Paul J. , Wargo, Jennifer A. , Tobin, Joshua W.D. , Seo, Yongwoo David , Gener‐Ricos, Georgina , Burton, Elizabeth M. , Lazar, Alexander J. , Ferrajoli, Alessandra

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e19511-e19511

10.1200/jco.2023.41.16_suppl.e19511 Get It

e19511 Background: CLL is the most prevalent adult leukemia and is associated with an increased risk of melanoma. CLL alters systemic immunity and can induce T-cell exhaustion, which may limit the efficacy of ICI in patients with CLL. Immune checkpoint inhibitors (ICI) have revolutionized management of AM, but data on ICI effectiveness have largely been restricted to clinical trials, thereby excluding patients with co-existing malignancies. We, therefore, sought to examine the efficacy of ICI for melanoma in patients with concomitant CLL and AM. Methods: In this international and multicentre retrospective study, review of clinical databases identified patients with concomitant CLL and AM treated with ICI from two US tertiary cancer centers (n = 39) and an Australian multi-institutional experience (AUS, n = 19). Objective response rates (ORR), defined as complete or partial response by RECIST v1.1, and survival outcomes (overall survival, OS, and progression-free survival, PFS) among patients with CLL and AM were assessed. Clinical factors associated with improved ORR and survival were explored. Results: Between 1997 and 2020, 58 patients with CLL were treated with ICI for concomitant AM. Among all patients with CLL and AM, ORR to ICI was 41% and median duration of response was 18 months. A majority were untreated for CLL (64%) at the time of ICI. Patients with prior history of treatment for CLL had significantly reduced ORRs (21% vs 51%, p = 0.04), PFS (3.6 vs. 14.6 months, p = 0.005), and OS (7.4 vs. 52.2 months, p = 0.002), compared to patients on observation for their CLL. Prior treatment with T-lymphocyte depleting chemoimmunotherapy (fludarabine, bendamustine, and alemtuzumab) was particularly associated with poor outcomes (median OS of 7.0 months, median PFS of 3.4 months). On univariate analysis, prior treatment for CLL, high risk CLL 17p deletion, and higher CLL Rai stage were associated with shorter PFS from ICI, though CLL treatment was the only factor independently associated with shorter PFS in the multivariate model (HR 6.5, [CI 2.1-20.3], p = 0.001]. Overall, 3 patients developed CLL progression while on ICI, though in two of these patients, the AM had an objective, durable clinical response to ICI. Overall, immune-related adverse events (irAE) occurred following 38% of ICI and rates of irAE were similar by CLL treatment status. Conclusions: Our case series of patients with concomitant CLL and melanoma demonstrate frequent, durable clinical responses to ICI However, those with prior chemoimmunotherapy treatment for CLL had significantly worse outcomes. We found that CLL disease course is largely unchanged by treatment with ICI.
Clues on Optical Coherence Tomography Leading to Diagnosis of Primary CNS Lymphoma (P2-9.012)
Moheb, Negar , Olsen, Timothy W. , Tobin, W. Oliver , Chen, John J.

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203794 Get It

Association of Specific “Critical” Demyelinating Lesions and Motor Impairment in Progressive Multiple Sclerosis: A Prospective Study (S46.008)
Ahmad, Rowaid, Jackson-Tarlton, Caitlin S. , Duffy, Dustin, Toledano, Michel , Lucchinetti, Claudia F. , Weinshenker, Brian G. , Kantarci, Orhun H. , Weinshenker, Brian G , Ahmad, Rowaid, Flanagan, Eoin P. , Messina, Steven A. , Tobin, W. Oliver , Pittock, Sean J. , Keegan, B. Mark

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202391 Get It

Long‐term clinical, imaging and cognitive outcomes association with MS immunopathology
Tillema, Jan‐Mendelt , Guo, Yong , Weigand, Stephen D. , Metz, Imke , Brück, Wolfgang , Giraldo‐Chica, Mónica , Lucchinetti, Claudia F. , Tobin, William Oliver, Metz, Imke , Lucchinetti, Claudia F , Kalinowska, Alicja , Tobin, W. Oliver , Lassmann, Hans , Port, John D.

Mayo Clinic

Annals of Clinical and Translational Neurology | February 10, 2023 | Volume: 10 | Issue: 3 | Pages: 339-352

10.1002/acn3.51723 | PMID 36759436 Get It

AbstractObjectiveIn this observational study on a cohort of biopsy‐proven central nervous system demyelinating disease consistent with MS, we examined the relationship between early‐active demyelinating lesion immunopattern (IP) with subsequent clinical course, radiographic progression, and cognitive function.MethodsSeventy‐five patients had at least one early‐active lesion on biopsy and were pathologically classified into three immunopatterns based on published criteria. The median time from biopsy at follow‐up was 11 years, median age at biopsy ‐ 41, EDSS ‐ 4.0. At last follow‐up, the median age was 50, EDSS ‐ 3.0. Clinical examination, cognitive assessment (CogState battery), and 3‐Tesla‐MRI (MPRAGE/FLAIR/T2/DIR/PSIR/DTI) were obtained.ResultsIP‐I was identified in 14/75 (19%), IP‐II was identified in 41/75 (56%), and IP‐III was identified in 18/75 (25%) patients. Patients did not differ significantly by immunopattern in clinical measures at onset or last follow‐up. The proportions of disease courses after a median of 11 years were similar across immunopatterns, relapsing–remitting being most common (63%), followed by monophasic (32%). No differences in volumetric or DTI measures were found. CogState performance was similar for most tasks. A slight yet statistically significant difference was identified for episodic memory scores, with IP‐III patients recalling one word less on average.InterpretationIn this study, immunopathological heterogeneity of early‐active MS lesions identified at biopsy does not correlate with different long‐term clinical, neuroimaging or cognitive outcomes. This could be explained by the fact that while active white matter lesions are pathological substrates for relapses, MS progression is driven by mechanisms converging across immunopatterns, regardless of pathogenic mechanisms driving the acute demyelinated plaque.
A second case of liraglutide-type localised amyloidosis
Muhammad, Sara, Tobin, W. Oliver , Dasari, Surendra , Theis, Jason D. , Vrana, Julie A., Naddaf, Elie , Tobin, W Oliver , Theis, Jason, Naddaf, Elie , McPhail, Ellen Darcy

Mayo Clinic

Amyloid | December 8, 2022 | Volume: 30 | Issue: 2 | Pages: 244-245

10.1080/13506129.2022.2151889 | PMID 36476295 Get It